c-Myc通过组蛋白去乙酰化酶1调控Y亚型小细胞肺癌免疫相关配体的作用
以Y亚型小细胞肺癌细胞系H196为对象,采用c-Myc抑制剂10058-F4和HDAC1抑制剂pyroxamide处理并与NK-92MI细胞共培养。结果显示c-Myc可能通过结合并抑制HDAC1促进MICA/B和CD47表达,同时参与抑制PD-L1和CD155表达。
要点
- 10058-F4组H196细胞MICA/B的MFI低于对照组,NK杀伤比例降低。
- pyroxamide组MICA/B的MFI高于对照组,可部分逆转10058-F4的抑制作用。
- c-Myc抗体沉淀组MICA启动子片段百分比高于IgG组,提示c-Myc-HDAC1复合物结合MICA/B启动子区。
核心结论
- c-Myc可能通过结合和抑制HDAC1促进Y亚型SCLC细胞MICA/B和CD47的表达,同时还参与抑制SCLC细胞PD-L1和CD155的表达。
研究设计与样本
- 以Y亚型SCLC细胞系H196为研究对象,分为对照组、c-Myc抑制剂10058-F4组、HDAC1抑制剂pyroxamide组以及10058-F4+pyroxamide组。
- 采用与NK-92MI细胞共培养体系确定对NK细胞功能的影响,Western blot和免疫共沉淀实验检测c-Myc对Ⅰ类HDAC的作用,流式细胞术检测c-Myc对MICA/B、CD47、PD-L1、CD155的调控作用,染色质免疫沉淀检测和实时荧光定量聚合酶链反应确定c-Myc-HDAC1对MICA/B的调控机制。
主要发现
- NK+H196+10058-F4组H196细胞死亡率(28.48±3.38)%低于NK+H196组(42.54±2.47)%,P<0.001。
- 10058-F4组H196细胞MICA/B的MFI(36.40±0.82)低于对照组(91.23±8.60),P<0.001。
- pyroxamide组H196细胞表面MICA/B的MFI(145.70±5.86)高于对照组(90.10±4.91),P<0.001;10058-F4+pyroxamide组MICA/B的MFI(54.60±2.88)高于10058-F4组(35.97±1.60),P<0.001。
- c-Myc抗体沉淀组MICA启动子基因片段百分比(0.125±0.037)高于IgG组(0.000 8±0.000 3),P=0.004,MICB有相似趋势。
- 10058-F4组H196细胞CD47的MFI(60.07±0.21)低于对照组(70.27±1.37),P<0.001;PD-L1的MFI(13.50±0.61)和CD155的MFI(829.70±41.19)高于对照组(9.23±0.94,P<0.01;496.00±4.36,P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the effect and mechanism of c-Myc on regulating the expression of immune-related ligands in Y subtype small-cell lung cancer (SCLC) characterized by high expression of immune-related molecules. Methods: The Y subtype SCLC cell line H196 was randomly divided into the control group, c-Myc inhibitor 10058-F4 group, histone deacetylase 1 (HDAC1) inhibitor pyroxamide group, and 10058-F4 plus pyroxamide group. The co-culture system with NK-92MI cells was used to determine the effect of H196 cells on the function of natural killer (NK) cells. Western Blotting and co-immunoprecipitation assays were used to detect the effect of c-Myc on class Ⅰ HDAC, and flow cytometry was used to detect the regulatory effect of c-Mycon CD47, programmed cell death ligand 1 (PD-L1), and CD155, which are highly expressed immune checkpoints in Y subtype SCLC, and major histocompatibility complex classⅠ-related chains A and (MICA/B), which is a poorly expressed immune-activating ligand in SCLC, and the role of HDAC. Chromatin immunoprecipitation (ChIP) assay and real-time quantitative polymerase chain reaction (RT-qPCR) were used to determine the regulatory mechanism of c-Myc-HDAC1 on MICA/B expression. Results: Inhibition of c-Myc decreased the mortality of H196 cells in the co-culture system and down-regulated the expression of MICA/B. Compared with the NK+H196 group [(42.54±2.47)%], the proportion of cells killed by NK-92MI cells in the NK+H196+10058-F4 group was lower [(28.48±3.38)%, P<0.001]. The mean fluorescence intensity (MFI) of MICA/B on the cells in the 10058-F4 group (36.40±0.82) was lower than that in the control group (91.23±8.60, P<0.001). And c-Myc could bind to HDAC1, whose protein level was up-regulated by 10058-F4 while the mRNA level was not. Compared with the cells in the control group (90.10±4.91), the MFI of MICA/B on the cells in the pyroxamide group was significantly increased (145.70±5.86, P<0.001), and the MFI of MICA/B on the cells in the 10058-F4+pyroxamide group (54.60±2.88) was significantly increased compared with the cells in the 10058-F4 group (35.97±1.60, P<0.001). The percentage of MICA promoter gene fragments in the c-Myc antibody precipitation group (0.125±0.037) was significantly higher than that in the IgG group (0.000 8±0.000 3, P=0.004). MICB had a similar trend, suggesting that the c-Myc-HDAC1 complex could bind to the promoter region of MICA/B. The MFI of CD47 on the cells in the 10058-F4 group (60.07±0.21) was significantly lower than cells in the control group (70.27±1.37, P<0.001), but the MFIs of PD-L1 (13.50±0.61) and CD155 (829.70±41.19) were significantly higher than those on the cells in the control group (9.23±0.94, P<0.01; 496.00±4.36, P<0.001, respectively). Conclusions: c-Myc may promote the expression of MICA/B and CD47 in Y subtype SCLC cells by binding and inhibiting HDAC1, while it may also be involved in inhibiting the expression of PD-L1 and CD155 in SCLC cells. 目的: 探讨以免疫相关分子高表达为特征的Y亚型小细胞肺癌(SCLC)中c-Myc对免疫相关配体表达的调控作用及机制。 方法: 以Y亚型SCLC细胞系H196为研究对象,分为对照组、c-Myc抑制剂10058-F4组、组蛋白去乙酰化酶1(HDAC1)抑制剂pyroxamide组以及10058-F4+pyroxamide组,采用与NK-92MI细胞共培养体系确定对自然杀伤(NK)细胞功能的影响,Western blot和免疫共沉淀实验检测c-Myc对Ⅰ类HDAC的作用,流式细胞术检测c-Myc对低表达的免疫激活性配体主要组织相容性复合体Ⅰ类链相关蛋白A和B(MICA/B)和Y亚型中高表达的免疫检查点分子CD47、细胞程序性死亡配体1(PD-L1)、CD155的调控作用及HDAC在其中的作用,染色质免疫沉淀检测和实时荧光定量聚合酶链反应确定c-Myc-HDAC1对MICA/B的调控机制。 结果: NK+H196+10058-F4组H196细胞死亡率[(28.48±3.38)%]低于NK+H196组[(42.54±2.47)%,P<0.001],10058-F4组H196细胞MICA/B的平均荧光强度(MFI)(36.40±0.82)低于对照组(91.23±8.60,P<0.001)。c-Myc能够与HDAC1结合,10058-F4作用下HDAC1蛋白表达明显上调、mRNA表达水平无明显变化。pyroxamide组H196细胞表面MICA/B的MFI(145.70±5.86)高于对照组(90.10±4.91,P<0.001),10058-F4+pyroxamide组H196细胞表面MICA/B的MFI(54.60±2.88)高于10058-F4组(35.97±1.60,P<0.001)。机制研究发现,c-Myc抗体沉淀组MICA启动子基因片段百分比(0.125±0.037)高于IgG组(0.000 8±0.000 3,P=0.004),MICB有相似趋势,c-Myc-HDAC1复合物结合MICA/B启动子区。10058-F4组H196细胞CD47的MFI(60.07±0.21)低于对照组(70.27±1.37,P<0.001),PD-L1的MFI(13.50±0.61)和CD155的MFI(829.70±41.19)高于对照组(9.23±0.94,P<0.01;496.00±4.36,P<0.001)。 结论: c-Myc可能通过结合和抑制HDAC1促进Y亚型SCLC细胞MICA/B和CD47的表达,同时还参与抑制SCLC细胞PD-L1和CD155的表达。.
引用
- Zhao PY, Sun XD, Li H, et al. [The effect of c-Myc on regulating the immune-related ligands in Y subtype small cell lung cancer through histone deacetylase 1]. Zhonghua Zhong Liu Za Zhi. 2024. PMID: 39622733. doi:10.3760/cma.j.cn112152-20230803-00058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。